Saphtx, Inc. · Newark, New Jersey
Protein therapeutics, translated from the academic lab.
We are a dedicated team of engineers, biologists, and inventors that have a passion for scientific innovation. We engineer protein-based therapeutic strategies for some of the biggest health issues we face. We are at the forefront of translating the innovations and inventions of engineers and scientists in Academia.
Two programs, one platform
Self-assembled peptides, applied twice
Saphtx engineers peptides that do two things at once: one domain binds a target, the other self-assembles into a fibril. The company has aimed that platform at the back of the eye and at SARS-CoV-2.
Neovascular eye disease
SAPHTx is an injectable hydrogel of naturally occurring amino acids, engineered to include an anti-angiogenic peptide, for AMD and diabetic retinopathy.
Antiviral peptides
Peptides designed to bind SARS-CoV-2 specifically and block its entry into human cells, developed under an NSF STTR Phase I award.
The platform
One peptide, two jobs
The platform is a mixture of hetero-peptides that co-assemble into functionalised β-sheets. One domain binds viral or tissue targets; the other drives assembly into fibrils whose displayed epitope depends on which peptides are mixed in, and in what ratio.
That makes the architecture tunable: the same manufacturing idea can be re-pointed at a different target.
Why it matters
What the platform buys
Two domains per peptide
One domain is designed to bind a specific viral protein; the other self-assembles into fibrils. The mix sets the epitope displayed on the surface.
Tunable composition
Fibril binding characteristics are determined by the types of peptides and their molar fractions, so the architecture can be re-pointed at a new target.
Multivalent by design
A fibril presents many binding sites at once, which is how it maintains strong binding to viral protein complexes.
Published
Nature Communications, 2024
“The lasting threat of viral pandemics necessitates the development of tailorable first-response antivirals with specific but adaptive architectures for treatment of novel viral infections. Here, such an antiviral platform has been developed based on a mixture of hetero-peptides self-assembled into functionalized β-sheets capable of specific multivalent binding to viral protein complexes.”
Work with us
Protein-based therapeutics, translated
Saphtx works with academic inventors to translate engineered proteins toward the clinic. If you would like to work with the company, its inbox is public.